Genmab — Oktober 2016
-
-
Tak Bongobob. Det var en god nyhed.
-
. If Seattle Genetics opts into a HuMax-ADC product at the end of Phase I, a payment would be due to Genmab and the companies would co-develop and share all future costs and profits for the product on a 50:50 basis. If Seattle Genetics does not opt in to a HuMax-ADC product, Genmab would pay Seattle Genetics fees, milestones and mid-single digit royalties on worldwide net sales of the product.
-
D. 9. november har vi Q&A med Genmab.
-
Casen er stærkere end nogensinde, og når 3B kommer med disse fede links og indspark om nye forsøg, så bliver man bare mere morgenglad. Kursen i dag og i morgen er kun interessant, hvis man vil købe. Det der for mig er interessant er FA-nyheder, da det er det som skal drive kursen over tid. Dejlige nyheder at starte dagen på

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind